- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05170334
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
March 18, 2024 updated by: H. Lee Moffitt Cancer Center and Research Institute
A Phase II Study of Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma.
The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors shrink or stop growing.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
32
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ahmad Tarhini, MD, PhD
- Phone Number: 813-745-8581
- Email: Ahmad.Tarhini@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Malik Hall
- Phone Number: 813-745-5170
- Email: Malik.Hall@moffitt.org
-
Principal Investigator:
- Ahmad Tarhini, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Male or female, aged >/= 18 years old
- Life expectancy of greater than 3 months in the opinion of the investigator
- Must have metastatic uveal melanoma, either initial presentation or recurrent, that is histologically diagnosed
- Participant must have ECOG performance status of 0-1
- Participant must have measurable disease, according to RECIST version 1.1
- Participants must have normal organ and marrow function as defined below:
- Leukocytes >3,000/mcL
- Absolute neutrophil count >1,500/mcL
- Platelets >100,000/mcL
- Total bilirubin within 1.5 x institutional upper limit of normal
- AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
- Creatinine within 1.5 x institutional upper limit of normal OR creatinine clearance >60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal
- An echocardiogram should be performed at baseline in all patients. Ejection fraction (EF) from baseline echocardiogram must be within the institutional limits of normal as determined by the reading cardiologist. The left ventricular ejection fraction (LVEF) must be ≥50%
- Participants on full-dose anticoagulants (e.g., warfarin) with PT INR >1.5 are eligible provided that both of the following criteria are met:
- a) The participant has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
- b) The participant has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- A participant may be treatment naïve. However, prior systemic treatments for metastatic uveal melanoma are allowed. There is no limit on the number of prior regimens for metastatic uveal melanoma. However, no prior therapy with a MEK inhibitor or an HDAC inhibitor
- Participant must be free of active brain metastasis by contrast-enhanced CT/MRI scans within 4 weeks prior to enrollment. If known to have prior brain metastases, these must have been adequately managed with standard of care radiation therapy, stereotactic radiosurgery or surgery prior to registration on the study
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 months after the end of any study drug administration
- For males of reproductive potential and/or with female partners of reproductive potential: use of condoms or other methods to ensure effective contraception with partner for 3 months after the last dose of any study drug.
Exclusion Criteria:
- Pregnancy or lactation
- Treatment with another investigational drug or other systemic intervention for uveal melanoma within 4 weeks of initiation of study drugs. Participants must not have radiotherapy within the preceding 4 weeks. Participants must have recovered from adverse events due to agents administered more than 4 weeks earlier
- Participants must be at least 4 weeks from major surgery and have fully recovered from any effects of surgery and be free of significant detectable infection
- Participants must not have other significant medical, surgical, or psychiatric conditions or require any medication or treatment that in the opinion of the investigator may interfere with compliance, make the administration of the study drugs hazardous or obscure the interpretation of AEs
- Participants must not have an active infection requiring current treatment with parenteral antibiotics
- Cardiac: No evidence of congestive heart failure, symptoms of coronary artery disease, myocardial infarction less than 6 months prior to entry, serious cardiac arrhythmias, or unstable angina
- CNS: No history of cerebrovascular accident or transient ischemic attacks within the past 6 months
- Serious or non-healing wound, ulcer, or bone fracture
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks of initiating study treatment
- Participants with clinically significant cardiovascular or cerebrovascular disease:
- History of cerebrovascular accident or transient ischemic attack within past 6 months
- Uncontrolled hypertension, defined as blood pressure >150/100 mm Hg or systolic BP >180 mm Hg if diastolic blood pressure <90 mm Hg, on at least 2 repeated determinations on separate days within past 3 months
- Myocardial infarction, CABG or unstable angina within the past 6 Months
- New York Heart Association grade III or greater congestive heart failure (Appendix E), serious cardiac arrhythmia requiring medication, unstable angina pectoris within past 6 months
- Clinically significant peripheral vascular disease within past 6 months
- Pulmonary embolism, DVT, or other thromboembolic event within past 6 months
- PT INR >1.5 unless the patient is on full-dose warfarin
- Participants who have other current malignancies are not eligible. Participants with other malignancies are eligible if they have been continuously disease free for > 3 years prior to the time of study registration (enrollment). Participants with prior history at any time of any in situ cancer, lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ are eligible. Participants with prior history of basal or squamous skin cancer are eligible
- History of retinal vein occlusion, uveitis refractory to ocular therapy, and symptomatic serous retinopathy or retinal pigment epithelial detachments
- Active requirement for or a history of corticosteroid systemic therapy in order to treat Interstitial lung disease (ILD) or pneumonitis
- The presence of a disorder that may impact absorption of study drugs, such as inability to take oral medication, requirement for IV alimentation, prior gastric resection, treatment for active peptic ulcer confirmed by endoscopy within the past 3 months, active GI bleed, GI malabsorption syndrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Binimetinib + Belinostat
Participants will receive binimetinib by mouth two times a day, every day during each cycle.
Each cycle will last for 21 days.
Participants will receive belinostat by intravenous infusion on days 1 through 5 of each cycle.
|
Binimetinib will be given at 45 mg orally twice daily during each cycle of 21 days, for up to 16 cycles.
Other Names:
Belinostat will be administered IV at 1,000 mg/m2 daily on days 1 to 5 every 21 days during each 21 day cycle, for up to 16 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: Up to 5 years
|
Overall Response Rate (ORR) defined as proportion of patients to have achieved a complete or partial response per RECIST v1.1 criteria.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival
Time Frame: Up to 5 years
|
Progression Free Survival (PFS) is defined as the length of time from start of study treatment to the earlier of the first documentation of disease progression or death from any cause.
|
Up to 5 years
|
Overall Survival
Time Frame: Up to 5 years
|
Overall Survival (OS) is defined as the length of time from start of treatment to date of death from any cause.
|
Up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ahmad Tarhini, MD, PhD, Moffitt Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2021
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
December 9, 2021
First Submitted That Met QC Criteria
December 9, 2021
First Posted (Actual)
December 27, 2021
Study Record Updates
Last Update Posted (Actual)
March 19, 2024
Last Update Submitted That Met QC Criteria
March 18, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Eye Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Uveal Diseases
- Neuroendocrine Tumors
- Nevi and Melanomas
- Eye Neoplasms
- Skin Neoplasms
- Melanoma
- Uveal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Histone Deacetylase Inhibitors
- Belinostat
Other Study ID Numbers
- MCC-20955
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Uveal Melanoma
-
GlaxoSmithKlineWithdrawnCancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
-
Delcath Systems Inc.Active, not recruitingMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
Alliance for Clinical Trials in OncologyWithdrawnMetastatic Uveal Melanoma | Advanced Uveal Melanoma | Unresectable Uveal Melanoma
-
National Cancer Institute (NCI)TerminatedMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the LiverUnited States
-
Memorial Sloan Kettering Cancer CenterIovance Biotherapeutics, Inc.RecruitingMelanoma | Metastatic Melanoma | Metastatic Uveal Melanoma | Uveal MelanomaUnited States
-
National Cancer Institute (NCI)Memorial Sloan Kettering Cancer Center; Institut Curie Paris; Moffitt Cancer...Active, not recruitingMetastatic Uveal Melanoma | Stage IV Uveal Melanoma AJCC v7United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbActive, not recruitingMetastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the Liver | Stage IV Uveal Melanoma AJCC v7United States
-
H. Lee Moffitt Cancer Center and Research InstituteRegeneron Pharmaceuticals; Genzyme, a Sanofi CompanyRecruitingMetastatic Uveal MelanomaUnited States
-
Vastra Gotaland RegionMerck Sharp & Dohme LLC; Syndax PharmaceuticalsCompletedMetastatic Uveal MelanomaSweden
Clinical Trials on Binimetinib
-
Pierre Fabre MedicamentEuropean Organisation for Research and Treatment of Cancer - EORTCActive, not recruitingMelanomaSpain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
-
National Cancer Institute (NCI)RecruitingHairy Cell LeukemiaUnited States
-
University of Alabama at BirminghamPacific Pediatric Neuro-Oncology Consortium; Array BioPharmaActive, not recruitingNeurofibromatosis Type 1 | Plexiform NeurofibromaUnited States
-
University Health Network, TorontoActive, not recruiting
-
PfizerTerminatedBrain MetastasesUnited States, Belgium, Australia, Argentina, Italy
-
PfizerPierre Fabre LaboratoriesTerminated
-
Leiden University Medical CenterPierre Fabre LaboratoriesRecruitingMelanoma Stage III | In-Transit Metastasis of Cutaneous MelanomaNetherlands
-
National Cancer Institute (NCI)RecruitingHairy Cell LeukemiaUnited States
-
Pierre Fabre Pharma GmbHPierre Fabre Pharma Austria; Pierre Fabre Pharma AGRecruitingMelanoma Stage IV | Melanoma Stage IIIAustria, Germany, Switzerland
-
OnKure, Inc.Active, not recruitingMelanoma | NRAS Gene Mutation | RAS MutationUnited States